GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tego Science Inc (XKRX:191420) » Definitions » EV-to-EBIT

Tego Science (XKRX:191420) EV-to-EBIT : -36.91 (As of May. 28, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Tego Science EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Tego Science's Enterprise Value is ₩133,819 Mil. Tego Science's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-3,625 Mil. Therefore, Tego Science's EV-to-EBIT for today is -36.91.

The historical rank and industry rank for Tego Science's EV-to-EBIT or its related term are showing as below:

XKRX:191420' s EV-to-EBIT Range Over the Past 10 Years
Min: -637.01   Med: 66.37   Max: 4924.47
Current: -36.91

During the past 11 years, the highest EV-to-EBIT of Tego Science was 4924.47. The lowest was -637.01. And the median was 66.37.

XKRX:191420's EV-to-EBIT is ranked worse than
100% of 668 companies
in the Drug Manufacturers industry
Industry Median: 16.995 vs XKRX:191420: -36.91

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Tego Science's Enterprise Value for the quarter that ended in Mar. 2024 was ₩159,537 Mil. Tego Science's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-3,625 Mil. Tego Science's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -2.27%.


Tego Science EV-to-EBIT Historical Data

The historical data trend for Tego Science's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tego Science EV-to-EBIT Chart

Tego Science Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 192.09 108.08 1,851.64 322.29 -39.14

Tego Science Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 236.56 -65.73 -41.89 -39.14 -44.00

Competitive Comparison of Tego Science's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Tego Science's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tego Science's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tego Science's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Tego Science's EV-to-EBIT falls into.



Tego Science EV-to-EBIT Calculation

Tego Science's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=133819.446/-3625.488
=-36.91

Tego Science's current Enterprise Value is ₩133,819 Mil.
Tego Science's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-3,625 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tego Science  (XKRX:191420) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Tego Science's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-3625.488/159536.5065
=-2.27 %

Tego Science's Enterprise Value for the quarter that ended in Mar. 2024 was ₩159,537 Mil.
Tego Science's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-3,625 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tego Science EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Tego Science's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Tego Science (XKRX:191420) Business Description

Traded in Other Exchanges
N/A
Address
8, Maagok central, gangseo-gu, Seoul, KOR
Tego Science Inc is a biotech company that researches and develops regenerative medicine. It is engaged in the production of epidermis and cornea wound healing solution. Its products include Holoderm, SkinBank, Kaloderm, and Neoderm. It also provides testing services.

Tego Science (XKRX:191420) Headlines

No Headlines